These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 31258010

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, Yu L, Huang XJ.
    Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
    [Abstract] [Full Text] [Related]

  • 3. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T.
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X, Pan J, Qiu H, Cen J, Xue Y, Chen S, Shen H, Yao L, Zhang J, Wu Y, Chen Y.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A, Eskazan AE.
    Cancer; 2018 Oct 01; 124(19):3806-3818. PubMed ID: 29694669
    [Abstract] [Full Text] [Related]

  • 9. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G, GIMEMA CML Working Party.
    Am J Hematol; 2017 Aug 01; 92(8):797-805. PubMed ID: 28466557
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 01; 16 Suppl():S96-S100. PubMed ID: 27131622
    [Abstract] [Full Text] [Related]

  • 12. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R, Ismail SM, Mohd Yunus N, Sulong S, Husin A, Abdullah AD, Hassan R.
    Malays J Pathol; 2020 Dec 01; 42(3):307-321. PubMed ID: 33361712
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.